Newton Charles W. 4

4 · Coherus Oncology, Inc. · Filed Jun 9, 2026

AI-generated summary of this filing

Updated Jun 9, 2026

Coherus Oncology (CHRS) Director Charles W. Newton Receives Award

What Happened

Charles W. Newton, a director of Coherus Oncology (CHRS), received awards on June 5, 2026: 30,000 restricted stock units (RSUs) and 60,000 derivative awards (reported as an "A" award) at $0.00 per share, total reported value $0. These awards are grants, not open-market purchases or sales, so no cash changed hands.

Key Details

Transaction date(s) and price(s): 2026-06-05; both awards reported at $0.00 per share.
Amounts: 30,000 RSUs + 60,000 derivative awards = 90,000 total units granted.
Vesting / exercisability (footnotes):
- F1 (RSUs): 30,000 RSUs convert to one share per RSU and vest 100% on the one‑year anniversary of June 3, 2026 (i.e., June 3, 2027), subject to continued service.
- F2 (derivative award): The underlying shares become exercisable/vest 100% on June 3, 2027, subject to continued service.
Shares owned after transaction: Not specified in the provided filing excerpt.
Filing date / timeliness: Form filed on 2026-06-09 for a 2026-06-05 transaction — this is several days after the trade and may be later than the standard Form 4 deadline (typically within two business days).

Context

These are forward-looking equity awards with time‑based vesting tied to continued service; they do not represent an immediate purchase or sale of shares and therefore do not by themselves indicate a buy/sell signal.
The 60,000 derivative awards appear to be option-like or other derivative instruments that will become exercisable/vest on the same vesting date; no cashless exercise or immediate disposition is reported.

Form 4

Period: 2026-06-05

Director

Transactions

Award
Common Stock
[F1]
2026-06-05+30,000→ 30,000 total
Award
Stock Option (Right to Buy)
[F2]
2026-06-05+60,000→ 60,000 total
Exercise: $1.45Exp: 2036-06-05→ Common Stock (60,000 underlying)

Footnotes (2)

[F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
[F2]The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.

Signature

/s/ Bryan McMichael, as Attorney in Fact for Charles W. Newton|2026-06-09

1 file